text:
News: Carevature's Limited Market Launch in US Brings Promise of Less Trauma and Quicker Recovery to Spinal Decompression Surgery Patients
TEL AVIV, Israel, Dec. 20, 2016 /PRNewswire/ -- Carevature announced today that its Dreal™ line of products has begun helping surgeons in the US achieve better outcomes in spinal decompression surgeries. Over 400 patients worldwide have been treated in clinical use, with outstanding safety and recovery results. Six centers in Massachusetts, New Hampshire, Connecticut and Texas, are currently taking part in Dreal™'s limited market release.
Traditional spinal decompression surgeries help patients with back or limb pain by removing the tissue (usually bone) that's putting pressure on the spinal nerves. In order to access the problematic tissue, surrounding tissue often needs to be removed. This can compromise spinal stability, and may require a spinal fusion procedure to connect the treated vertebrae and restore stability.
Carevature's Dreal™'s unique curved design enables orthopedic surgeons and neurosurgeons to perform better spinal decompression more quickly and with less trauma to the area. Preservation of the surrounding tissue may reduce the need for spinal fusion procedures or simplify these procedures when fusion cannot be avoided.
Use of Dreal™ reduces operating room time and hospitalization time for spinal decompression patients. Spinal decompression patients treated with Dreal™ can be released from the hospital much faster than those treated with standard surgical tools. Avoidance of spinal fusion procedures can save the healthcare system tens of thousands of dollars per patient.
"I am using the Dreal™ for all my decompression cases" said Richard Guyer, MD, spine surgeon, co-founder of the Texas Back Institute in Plano, TX and past president of the North American Spine Society.
"This is the only device that allows the surgeon to decompress severely stenotic neuroforamen from the inside out while still leaving the anatomy intact and eliminating the need for fusion. There have been other devices but none are as easy to use as this, as it requires no new skills. While hundreds of thousands of lumbar decompressions are performed in the US every year, I believe that this device has the potential of reducing the number of fusions in these patients."
"This is a significant milestone for the entire Carevature team," said Yosi Weitzman, Carevature Founder and CEO. "It is exciting to see our hard work and dedication, make a difference to patients' lives and well-being. We look forward to introducing Dreal™ to more centers as part of our full commercial launch, planned for 2017."
About Carevature
Carevature Medical Ltd. is a privately held medical device company, dedicated to the development of advanced orthopedic surgery solutions. Carevature Medical was founded in 2011 and is headquartered in Rehovot, Israel.
Carevature is now focused on its flagship line of products for spinal indications, Dreal™, the first and only curved device powerful enough to efficiently cut bone and small enough to be used in spine surgery and neurosurgery. www.carevature.com
Shani Sarid
Shani@pearlcom.co.il
Published at PRNewsWire
News: Intrinsic Therapeutics announces the Filing of PMA Application for its Barricaid® Anular Closure Device for Lumbar Discectomy Patients
BOSTON, Dec. 21, 2016 /PRNewswire/ -- Intrinsic Therapeutics, Inc. announced today that the filing of its Pre-Market Approval (PMA) application with the Food & Drug Administration (FDA) for the Barricaid® Anular Closure device is complete. Barricaid has been shown to improve the outcomes of patients undergoing discectomy for herniated lumbar discs to relieve sciatica pain.
"Approximately 1 million discectomies are performed every year around the globe and 40% of these patients will leave the operating room after discectomy with a large hole remaining in the outer rim of the disc, the anulus," said Professor Douglas Klassen, Chief of Neurosurgery at St. Bonifatius Hospital, Lingen, Germany. "By simply sealing these large defects, patient outcomes can be improved significantly."
The Barricaid Anular Closure device, designed to prevent repeat disc herniations in patients undergoing back surgery to treat sciatica, is the first of its kind to be the subject of a prospective, randomized, superiority trial involving patients who are at higher risk for revision discectomy surgery to alleviate recurrent pain resulting from reherniation. The PMA submission was based on the 2-year outcomes of 554 trial participants. Inclusion criteria for the study ensured enrollment of only subjects with a high risk of reherniation, subsequent reoperation, and rehospitalization.
"Today, quality patient care and the utilization of healthcare resources are scrutinized more than ever," said Dr. Matthew McGirt, a Neurosurgeon at Carolina Neurosurgery & Spine Associates in Charlotte, North Carolina. "Technologies that demonstrate fewer repeat surgeries when compared to traditional treatment will fit into the paradigm of improving outcomes and conserving healthcare resources."
Further supported by the clinical success demonstrated in earlier single-arm studies, Barricaid today stands alone as a unique treatment device for patients wishing to minimize risk of reherniation and resultant reoperations. Additional benefits include reduction in serious adverse events, episodic pain events and early hospital readmissions (at 30, 60 and 90 days).
"We are thrilled to have reached this important milestone and move into the next phase with FDA," said Cary Hagan, Intrinsic's President and Chief Executive Officer. "Parallel to the PMA approval process, we continue to focus our efforts on market access including reimbursement pathways for this compelling new technology with a sharp focus on delivering a solid Health Economic proposal to payers and hospital systems."
About Intrinsic Therapeutics
Intrinsic Therapeutics is a medical device company focused on delivering a safe treatment to improve efficacy in patients who are at a disproportionately high risk of requiring repeat surgeries due to reherniation following lumbar discectomy surgery. Intrinsic currently markets and sells the Barricaid in Europe, Australia, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. In the United States, Intrinsic Therapeutics is seeking regulatory approval of the Barricaid Anular Closure device. See http://www.in-thera.com for more information.
Barricaid is a registered trademark of Intrinsic Therapeutics, Inc.
This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to the potential approval by the FDA of the Company's PMA submissions for the Barricaid Anular Closure device and the success of the Company's launch preparedness efforts. These forward-looking statements are based upon Intrinsic's current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with the commercialization and market acceptance of, and customer demand for, the Barricaid Anular Closure device; the uncertain and time-consuming regulatory process, including the risks that the Company may be required to complete additional clinical trials in order to obtain approval of its PMA submissions; that the Company may otherwise encounter unanticipated difficulties complying with the regulatory requirements related to the Barricaid Anular Closure device or that the Company's PMA submissions might not be approved by the FDA in a timely manner or at all; that the Company may not have the resources to support multiple regulatory submissions; adverse market and economic conditions; and other risks You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Intrinsic does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.
Cary P. Hagan, CEO
Intrinsic Therapeutics, Inc.
clinical@in-thera.com
News: CartiHeal Announces FDA IDE Approval of Its Agili-C Implant for the Treatment of Joint Surface Lesions
KFAR SABA, Israel, Dec. 20, 2016 /PRNewswire/ -- CartiHeal (2009) Ltd., developer of a cell-free, off-the-shelf implant for use in cartilage and osteochondral defects, announced today the FDA approval of the Investigational Device Exemption (IDE) application submitted by CartiHeal for their Agili-C™ implant, towards a PMA application.
The 2 year-long pivotal study will involve a minimum of 250 patients in US and OUS centers. The study is aimed to show superiority of the Agili-C™ implant over surgical standard of care, i.e. microfracture and debridement, in the treatment of cartilage/osteochondral defects in both osteoarthritic knees and in knees without degenerative changes, making it the first approved study of such broad indications using a single implant.
The study is designed as a prospective, multicenter, open-label, randomized and controlled trial, involving up to 3 lesions in the same joint and with a total treatable area of 1-7cm2.
Agili-C™ was implanted in a series of clinical trials conducted in leading centers in Europe and Israel, in over 220 patients with cartilage lesions in the knee, ankle and great toe. In these trials the implant was used for the treatment of a wide spectrum of cartilage lesions, according to its CE Mark, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis.
Results of these prior investigations demonstrated the potential for cartilage regeneration and remodeling of the underlying subchondral bone, along with pain and symptom relief.
"Pivotal studies performed to date were always focused on small, focal and isolated cartilage lesions in a narrowly defined patient group, which does not represent most of the 'real-life' cases," explains Dr. Ken Zaslav, President of the International Cartilage Repair Society (ICRS) and a member of CartiHeal's Clinical Advisory Board. "Based on the robust clinical data of the Agili-C™ implant, FDA has allowed for the first time, treatment indications ranging from single focal defects to multiple defects in osteoarthritis of the knee, which is what us surgeons see on a daily basis. Moreover, this exciting study will compare two control modes in a single arm: microfracture for the treatment of focal lesions and debridement for patients with osteoarthritis."
"Over the last few years we've conducted a series of clinical studies in leading centers to learn which kind of patients can benefit from the Agili-C™ implant," says Nir Altschuler, CartiHeal's founder and CEO. "Together with our Clinical Advisory Board we designed a study that targets a large patient population who can potentially benefit from this implant. We are very pleased that FDA approved our study design, and believe that the Agili-C™ implant will prove to be an ideal treatment for a variety of cartilage lesions in patients who wish to return to a painless and active lifestyle, and currently don't have good alternatives."
About CartiHeal
CartiHeal, a privately-held medical device company headquartered in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.
Backed by extensive pre-clinical and clinical data, its flagship product Agili-C™, an aragonite-based biodegradable scaffold, has been shown to promote restoration of hyaline cartilage and remodeling of its underlying subchondral bone through a natural process, without the use of cells or growth factors.
Clinical results in the knee, ankle and big toe demonstrated the potential of significant improvement in pain reduction, as well as reduction in related symptoms - through a simple, single-step implantation procedure.
In the United States, the Agili-C is an investigational device that is limited to use in the IDE study. It is not available for sale.
Caty Pearl | Caty@pearlcom.co.il | +972-548081020
News: ZipLine® Medical Receives China Food and Drug Administration (CFDA) Approval for Non-Invasive Zip® Skin Closure System
CAMPBELL, Calif.--(BUSINESS WIRE)--ZipLine® Medical, Inc., an innovator in skin closure, today announced China Food and Drug Administration (CFDA) approval and commercial availability of its Zip® Surgical Skin Closure device in the region. This clearance will give the company access to the $543 million Chinese wound closure device market serving over 40 million procedures, including growing specialties where the Zip has shown significant benefit, such as orthopedics for total joint replacement and obstetrics for Cesarean-section and hysterectomy procedures. ZipLine Medical recently featured the Zip at the prestigious 11th International Congress of the Chinese Orthopaedic Association, held in Beijing.
"The non-invasive Zip closure is ideally suited for the healthcare market in China, in light of its large and growing procedure volume, need for cost-effective and efficient solutions, and appreciation of aesthetics"
The Zip is a non-invasive, efficient and easy-to-use wound closure device that replaces traditional sutures, staples and glue for surgical incisions and lacerations. It results in a comfortable, secure wound and the device's unique force distribution system results in high patient comfort and excellent scar quality. The Zip's micro-adjustability and reversibility provide surgeons with precise control and flexibility during closure. Because application and removal are simple, clinicians can delegate the closure task and, at the clinician's discretion, patients may remove the Zip at home. Unlike staples or sutures, there are no skin punctures with the Zip, so scarring is minimal and there are no added pathways for bacteria to enter. The Zip's benefits have been demonstrated in clinical studies in orthopedic total-joint arthroplasty, cardiothoracic surgery, electrophysiology and dermatology.
"The non-invasive Zip closure is ideally suited for the healthcare market in China, in light of its large and growing procedure volume, need for cost-effective and efficient solutions, and appreciation of aesthetics," said ZipLine Medical's President and Chief Executive Officer John Tighe. "We look forward to working with our team of distribution partners across China to bring the speed, safety, comfort and convenience of Zip to Chinese patients."
ABOUT ZIPLINE MEDICAL
ZipLine Medical is an innovator in cost-effective, non-invasive surgical skin closure devices that deliver high patient satisfaction and surgeon efficiency. Zip Surgical Skin Closure devices have been used in more than 50,000 cases and in over 30 countries worldwide. ZipLine Medical was founded by Amir Belson, M.D., and is headquartered in Campbell, CA. For more information, visit www.ziplinemedical.com.
Zip® Surgical Skin Closure devices are classified by the U.S. FDA as 'Class I, 510(k) Exempt' and have received the CE Mark in addition to CFDA approval.
Chronic Communications, Inc.
Michelle McAdam, 310-902-1274
michelle@chronic-comm.com
Published at BusinessWire
News: Anika Wins CE Mark Approval For ORTHOVISC®-T To Relieve Pain and Restore Function of Tendons Damaged by Chronic Injury
BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid "HA" technology, today announced that it received CE Mark approval for ORTHOVISC-T (sodium hyaluronate for peritendinous injection), a treatment indicated to relieve pain and restore function in tendons affected by chronic lateral epicondylosis. ORTHOVISC-T is designed to provide lubrication to the site of the damaged tendons to promote tendon gliding and to provide an environment to support tendon repair. ORTHOVISC-T is the latest addition to Anika's product portfolio, which includes, among other products, HYALOFAST®, a biodegradable, hyaluronic acid-based scaffold for hyaline-like cartilage regeneration to treat cartilage injuries and defects. Both HYALOFAST and ORTHOVISC-T are CE Marked and pending regulatory submission in the United States.
"We're excited to announce the timely European approval of ORTHOVISC-T for the treatment of pain associated with one of the most common overuse injuries to connective tissues, the condition commonly described as tennis elbow," said Charles H. Sherwood, Ph.D., President and Chief Executive Officer. "The availability of ORTHOVISC-T not only promises to help millions of people in Europe find relief from this painful condition, it also expands our global foothold in orthopedic medicine and provides real-world clinical experience to inform our path towards regulatory submission in the U.S."
ORTHOVISC-T is administered via injection into the site of injury to relieve pain and restore function of tendons damaged by chronic injury and overuse, as often seen in tennis elbow. ORTHOVISC-T consists of a biocompatible, non-animal-derived and non-inflammatory formulation of hyaluronic acid similar to those found in the company's best-selling viscosupplements, ORTHOVISC and MONOVISC®.
"Degenerative overuse injuries to tendons are a leading cause of pain and restricted activity, and, until now, treatments were limited to oral medications, physical and/or occupational therapy, and corticosteroid injections," said Peter M. Prokopis, M.D., Hand and Upper Extremity Specialist at Sports Medicine North, a Massachusetts-based sports medicine clinic. "ORTHOVISC-T is a natural and effective solution that not only relieves pain, but also addresses the source of pain and discomfort and promotes natural resolution of the symptoms and ultimate recovery."
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika's orthopedic medicine portfolio includes ORTHOVISC®, MONOVISC®, and CINGAL®, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST®, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.
The statements made in the last sentence of the first paragraph of this press release, which are not statements of historical fact, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, those relating to the pendency of the Company's regulatory submissions for Hyalofast and Orthovisc-T in the United States. The Company's actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including (i) the Company's ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company's ability to obtain pre-clinical or clinical data to support domestic and international pre-market approval applications or 510(k) applications, or to timely file and receive FDA or other regulatory approvals or clearances of its products; (iii) that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (iv) the Company's research and product development efforts and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (v) the cost effectiveness and efficiency of the Company's clinical studies, manufacturing operations, and production planning; (vi) the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (vii) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (viii) the Company's ability to successfully commercialize its products, in the U.S. and abroad; (ix) the Company's ability to provide an adequate and timely supply of its products to its customers; (x) the Company's ability to continue to successfully manage Anika Therapeutics S.r.l.'s business; and (xi) the Company's ability to achieve its growth targets. Additional factors and risks are described in the Company's periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC's website at www.sec.gov. Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.
For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Pure Communications
Susan Heins, 864-286-9597
News: Stryker Orthopaedics to compensate additional eligible U.S. patients who had surgery to replace their Rejuvenate Modular-Neck and/or ABG II Modular-Neck Hip Stems
Kalamazoo, Michigan - December 19, 2016 - Stryker Corporation (NYSE:SYK) announced that Howmedica Osteonics Corp. (referred to as "Stryker Orthopaedics"), a subsidiary of Stryker Corporation, and Court-appointed committees of attorneys representing Rejuvenate Modular-Neck and ABG II Modular-Neck plaintiffs in New Jersey Multicounty and Federal Multidistrict litigations reached an agreement to compensate additional eligible U.S. patients who had surgery to replace their Rejuvenate Modular-Neck hip stem and/or ABG II Modular-Neck hip stem, known as a revision surgery, prior to December 19, 2016. This follows an initial 2014 Settlement Program that covered patients who had a revision surgery prior to November 3, 2014. In that initial program, over 95% of eligible patients enrolled. Under this new agreement, additional patients are now eligible to participate and may apply for compensation.
The Settlement Agreement will help bring to a close significant Rejuvenate Modular-Neck and ABG II Modular-Neck litigation activity in the U.S. However, some lawsuits will remain and Stryker Orthopaedics will continue to defend against remaining claims. For more information about the Settlement Program, please visit strykermodularhipsettlement.com.
Based on the information that has been received to date, no additional charge to earnings is being recorded in connection with entering into the Settlement Agreement. The final outcome of this matter is dependent on many variables that are difficult to predict. The ultimate cost to entirely resolve this matter may be materially different than the amount of the current estimate. It is expected that a majority of the payments under the Settlement Agreement will be made by the end of 2017.
Settlement Program
For eligible U.S. Patients Who Had Surgery to Remove Their Rejuvenate Modular-Neck Hip Stem and/or ABG II Modular-Neck Hip Stem Prior to December 19, 2016.The Settlement Program is available to eligible United States patients who had revision surgery for reasons related to the voluntary recall of the modular-neck hip stems prior to December 19, 2016. Patients eligible for compensation under the Settlement Program should speak with their attorney, if they have one, or contact the Settlement Program claims administrator at www.strykermodularhipsettlement.com or 1-855-382-6404. Patients do not need an attorney to participate in the Settlement Program.
For U.S. Patients Who Have Not Had Surgery to Remove their Rejuvenate Modular-Neck Hip Stem and/or ABG II Modular-Neck Hip Stem Prior to December 19, 2016. The existing Broadspire program offering support for recall-related care continues to be available. Patients are encouraged to visit patients.stryker.com/modularneckstems or call 1-888-317-0200 for more information. Patients do not need an attorney to participate in the Broadspire program.
Stryker is one of the world's leading medical technology companies and, together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. Stryker is active in over 100 countries around the world. Please contact us for more information at www.stryker.com.
For investor inquiries please contact:
Katherine A. Owen, Stryker Corporation, 269-385-2600 orkatherine.owen@stryker.com
For media inquiries please contact:
Yin Becker, Stryker Corporation, 269-385-2600or yin.becker@stryker.com
Published at Stryker News
News: Amedica Announces Positive Scientific Data and Re-files FDA Submission
SALT LAKE CITY, UT--(Marketwired - Dec 19, 2016) - Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, announced encouraging results from a recent study showing rapid bone growth into porous silicon nitride. Explants of the company's porous silicon nitride from a large-animal model demonstrated bone healing into the material just four weeks after implantation. "We anticipate these preliminary findings will be confirmed with additional retrieval data in the near future. The porous silicon nitride sample used in this study is the cancellous-structured ceramic (CsC) used in the center of our composite cervical implants that were the subject of recent FDA communications," said Dr. B. Sonny Bal, CEO and President of Amedica Corporation.
Amedica has re-filed an application with the FDA, with a modified CsC-based cervical implant that is comparable to Amedica's own commercially-available Valeo®C cervical implants. "With this submission, the goal is to introduce our proprietary CsC technology platform into the U.S. market without further delay," said Dr. Bal.
About Amedica Corporation
Amedica is focused on the development and application of spinal interbody implants made with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing implants for other biomedical applications, such as wear- and corrosion-resistant hip and knee bearings, and dental implants. The Company's products are manufactured in its ISO 13485 certified manufacturing facility, and it has a partnership with Kyocera, one of the world's largest ceramic manufacturers. Amedica's FDA-cleared and CE-marked spine products are currently marketed in the U.S. and select markets in Europe and South America through its distributor network, and OEM and private label partnerships.
For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.
This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated within this press release. A discussion of those risks and uncertainties can be found in Amedica's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 23, 2016, and in Amedica's other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.
Amedica IR
IR@amedica.com
Published at MarkeWired
News: Providence Medical Technology Announces New Equity Financing Of $10.5 Million
WALNUT CREEK, Calif., Dec. 19, 2016 /PRNewswire/ -- Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, today announced the closing of $10.5 million in new equity financing for the company. The proceeds will be used to further commercialize and expand its portfolio of cervical-fusion technology.
Providence's family of cervical-fusion products now includes DTRAX® Spinal Systems, CAVUX™ Cervical Cages, ALLY™ ScrewSystems, and BIOLOGIX™ Allograft Bone. The Company's cervical-fusion products are provided in sterile packaging for single use and fill critical gaps in the continuum of cervical spine care.
New investor MVM Life Science Partners ("MVM") led the financing and will join the Providence Board of Directors. Stanmore Medical Investments, Aphelion Capital, and existing private investors also participated in the round.
Dr. Bali Muralidhar, a partner at MVM said, "Providence's unique product suite addresses key unmet needs in cervical spine fusion surgery. MVM is delighted to support the business through the next phase of growth and to be working with such a high-quality CEO and management team." Providence Chief Executive Officer Jeff Smith commented, "I am thrilled MVM is joining our group of supportive investors. MVM's deep scientific expertise and success globally commercializing medical technologies make them an ideal partner for Providence."
"We are excited by the continued growth of our business and wide adoption of our innovative, cervical-fusion technology," said Smith. "With our expanding product offering and growing body of clinical evidence, surgeons are increasingly choosing Providence. We are so pleased that our products are resulting in positive patient outcomes and resonating with spine surgeons and hospital administrators alike."
About MVM Life Science Partners LLP.
MVM Life Science Partners LLP, founded in 1997, is a leading global healthcare Venture Capital / Private Equity firm based in London and Boston who manages four funds totaling over US$700 million. MVM invests across the Life Sciences market including biopharmaceuticals, diagnostics, drug delivery, gene therapy, medical devices, OTC medicines, research tools and vaccines. The MVM team has broad experience across the Life Science and Venture Capital / Private Equity markets. For more information: www.mvm.com
About Providence Medical Technology, Inc.
Providence Medical Technology, Inc. is a privately-held medical device company developing innovative solutions addressing the $2 billion worldwide cervical spine market. The company is focused on commercializing the DTRAX platform of single-use, tissue-sparing instruments and CAVUX implants for cervical fusion, as well as other technologies that improve cervical spine procedures for both physicians and patients. For more information, visit www.providencemt.com.
News: Latest Australian Joint Registry Data Confirm Positive Early Results For the ATTUNE® Knee System
SOLOTHURN, Switzerland--(BUSINESS WIRE)--DePuy Synthes, part of the Johnson & Johnson Family of Companies, today announced that implant survivorship data from the 2016 Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) confirm positive early results for DePuy Synthes' ATTUNE® Knee System.1 These data add to recent UK Joint Registry evidence which indicate that survivorship for the ATTUNE Knee compares favorably to other cemented knee systems in its class.2 In addition, recently-presented interim data on two studies suggest improved patient reported outcomes measures with the ATTUNE Knee compared to other leading knee systems.3
"These promising early results are encouraging for patients, healthcare providers and payers, and underline the importance of our robust evidence generation program for the ATTUNE Knee"
Per the 2016 AOANJRR, in which 4,831 ATTUNE Knees are being tracked, the ATTUNE Knee estimated cumulative percent revision was 0.5% (ATTUNE Cruciate Retaining Knee) and 0.4% (ATTUNE Posterior Stabilized Knee) at one year.1 This compares favorably to the overall class of cemented total knee arthroplasty (TKA) at one year, which has an estimated cumulative percent revision of 1.0%.1
In addition, interim results from an ongoing study of patients implanted with ATTUNE Posterior Stabilized (PS)TKA Knees showed a reduced incidence of symptomatic crepitus that was half of that compared to non-ATTUNE PS TKA Knees at a minimum of one year .4
"There is a steady cadence of evidence for the ATTUNE Knee that suggests improved outcomes and functional performance3,5" said Paul Voorhorst, Vice President of Clinical Research for DePuy Synthes Joint Reconstruction. "We are committed to ongoing monitoring of both the outcomes and economic benefits of this new technology."
A large U.S. hospital administrative database review showed results that ATTUNE Knee patients in this review had a 39% lower adjusted odds of discharge to a skilled nursing facility compared to patients in this review who received a TKA with a Triathlon®Knee.6
"These promising early results are encouraging for patients, healthcare providers and payers, and underline the importance of our robust evidence generation program for the ATTUNE Knee," said Christina Farup, Vice President, Health Economics and Market Access, Johnson & Johnson Medical Devices. "We designed the ATTUNE Knee System with both patients and providers in mind to help health care systems increase patient satisfaction, improve clinical outcomes and reduce overall health care costs."
The ATTUNE Knee evidence generation program gathers information from many sources, including other joint registries. In addition to the AOANJRR, the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man (NJR) also indicated that the ATTUNE Knee System compares favorably to other cemented total knee systems in its class.2 Per the 2016 NJR, the ATTUNE Knee estimated cumulative percent revision was 1.39% at 3 years (98.61% survivorship) for 4,463 knees, comparing favorably to the class of Cemented TKA that has an estimated cumulative percent revision of 1.50%.2
Advancements in TKA surgery systems, such as the ATTUNE Knee, may not only benefit patients, but the healthcare system as a whole because patients may be able to leave the hospital sooner and return to normal activity. A 2013 study published in The Journal of Bone and Joint Surgery found that societal savings, such as decreased disability costs, return to independent living, and increased work productivity, far exceeded direct costs [of TKA surgery].7
Global thought-leader surgeons, engineers, and experts in fields of study such as kinematics, anthropometrics, polyethylene wear and design collaborated to develop and test the ATTUNE Knee System. Extensive research and science has gone into the design to help improve functional outcomes for patients, performance for surgeons, and efficiency for providers.
About DePuy Synthes
DePuy Synthes, part of the Johnson & Johnson Family of Companies, provides one of the most comprehensive portfolios of orthopaedic solutions in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, neurological, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.
The third party trademarks used herein are the trademarks of their respective owners.
©Johnson & Johnson Medical Limited. 2016. All rights reserved.
Registered Office: Johnson & Johnson Medical Limited, PO BOX 1988, Simpson Parkway, Livingston, West Lothian, EH54 0AB, United Kingdom. Incorporated and registered in Scotland under company number SC132162
1. Australian Orthopaedic Association National Joint Replacement Registry Annual Report. (2016). Tables KT9 and KT22. Retrieved from: https://aoanjrr.sahmri.com/documents/10180/275066/Hip%2C%20Knee%20%26%20Shoulder%20Arthroplasty
2. National Joint Registry for England, Wales, Northern Ireland and the Isle of Man Annual Report. (2016). Tables 3.28 and 3.24 (a). Retrieved from: http://www.njrcentre.org.uk/njrcentre/Portals/0/Documents/England/Reports/13th%20Annual%20 Report/07950%20NJR%20Annual%20Report%202016%20ONLINE%20REPORT.pdf
3. Hamilton, W., Himden, S., Brenkel, I., Clatworthy, M., Dwyer, K., Lesko, J. and Kantor, S. Early Patient Reported Outcomes With New Primary vs. Contemporary Total Knee Arthroplasty: A Comparison of Two Worldwide, Multi-Center Prospective Studies. International Society for Technology in Arthroplasty (ISTA): e-Poster, 5-8 October 2016, Boston, MA. Based on interim data. The leading knee systems included: 89% P.F.C.® SIGMA®, 3% Zimmer NexGen®, 7% Stryker Triathlon®, 1% Other.
4. Toomey, S., Daccach, J., Shah, J., Himden, S., Lesko, J. and Hamilton, W. Comparing the Incidence of Patellofemoral Complications in a New Total Knee Arthroplasty (TKA) System vs. Currently Available Products in Two, Worldwide, Multi-Center, Prospective Clinical Studies. While not statistically significant, the trend is promising and follow-up is ongoing. Based on interim data.
5. Clatworthy, M. (2015). An Early Outcome Study of the ATTUNE® Knee System vs. the SIGMA® CR150 Knee System. DePuy Synthes Companies White Paper. DSUS/JRC/0814/0418(1). In an IRB approved early outcomes study, physiotherapists collected data on 40 patients implanted with ATTUNE Knees and 40 patients with SIGMA® CR150 Knees. The results demonstrated that patients implanted with the ATTUNE Knee had statistically significant improvements in some early outcomes, other outcomes demonstrated a trend favoring the ATTUNE Knee, and some outcomes were equivalent.
6. Etter, K., Lerner, J., de Moor, C, Yoo, A., Kalsekar, I. (2016). PMD10-Comparative Effectiveness of ATTUNE® Versus Triathlon®Total Knee Systems: Real-World Length of Stay and Discharge Status." Value in Health 19(3): A298. Premier Perspective™ Database analysis including 38 hospitals, representing 1,178 primary, unilateral TKAs with the ATTUNE® Knee and 5,707 primary, unilateral TKAs with Triathlon™. The analysis found that the patients implanted with the ATTUNE Knee had statistically shorter length of stay and were more frequently discharged home vs. a skilled nursing facility compared to the TKAs with Triathlon®.
7. Ruiz D, Koenig L, Dall T, et al. The Direct and Indirect Costs to Society of Treatment for End-Stage Knee Osteoarthritis. J Bone Joint Surg Am., 2013; 95: 1473-80.
DePuy Synthes
Jennifer Holden
Sr. Manager, Communications
jholden2@its.jnj.com
News: OrthoSpace Announces Publication of Positive Results for the InSpace™ System in the Treatment of Massive Rotator Cuff Tears
OrthoSpace announced the publication of positive results for their InSpace System in the surgical treatment of massive rotator cuff tears (MRCTs). The system was demonstrated to improve shoulder function and reduce pain in a challenging patient population.
CAESAREA, ISRAEL (PRWEB) DECEMBER 16, 2016
OrthoSpace Ltd. ("OrthoSpace" or "Company") today announced a publication in the December issue of Musculoskeletal Surgery citing positive results for their InSpace System in the surgical treatment of massive rotator cuff tears (MRCTs). Patients undergoing the InSpace procedure experienced durable improvements in shoulder function and reductions in shoulder pain at 12 months of follow-up, demonstrating the benefits of InSpace as an effective alternative to existing surgical treatments.
The InSpace System consists of a biodegradable balloon spacer that is implanted in the subacromial space of the shoulder. InSpace is designed to address the challenges of MRCTs where surgery often fails and for which there is not current consensus or definitive guidelines for optimal surgical treatment. The procedure may be performed arthroscopically, or under fluoroscopy guidance, as presented in the study.
Patients with advanced age, diminished health status and comorbidities such as cardiovascular disease may be at a higher risk for complications when subjected to general anesthesia. The option to receive InSpace under fluoroscopy guidance addresses the unmet needs associated with this patient population, as the procedure is performed under local anesthesia.
"InSpace has been demonstrated to improve patient shoulder function and reduce pain in a difficult-to-treat population where conservative options have been exhausted and surgery under anesthesia would pose high risks to the patient," said Enrico Gervasi, M.D., the study's principal investigator and the Director of Orthopedic and Trauma Surgery at Latisana Civil Hospital at Udine, Italy. "Further, the procedure is technically easy to perform, taking only ten minutes to deploy the spacer, and can be performed under local anesthesia in the outpatient setting."
This ongoing clinical study of the InSpace System will ultimately enroll up to 45 patients, all of whom will be followed for up to 24 months. The study population consists of elderly patients who are not candidates for surgery under general anesthesia and who did not respond to conservative treatment, including steroid injections and physical therapy. This publication represents a planned interim analysis of the first 15 patients enrolled, who were considered evaluable upon reaching 12 months of follow-up. All 15 patients in this cohort experienced overall improvements in shoulder function, as measured by the Constant Score and the American Shoulder and Elbow Surgeons Evaluation Form (ASES). Of these patients, 85% showed a clinically significant improvement in their Constant Score. Improvements were observed beginning at 6 weeks post treatment and sustained for at least 12 months post-treatment. Additionally, patients reported significant improvements in pain scores.
"We are pleased with these results from Dr. Gervasi and colleagues. These data reinforce and continue to build on the existing data supporting the use of InSpace for patients with massive rotator cuff tears," said Itay Barnea, CEO of OrthoSpace. "The cases represent an unmet clinical need, and we are proud to offer additional surgical options for patients who are suffering from pain and immobility associated with this difficult indication."
About OrthoSpace Ltd.
OrthoSpace is a privately held medical device company located in Caesarea, Israel. The Company's product, InSpace, is an orthopedic biodegradable balloon system that is simple, safe and a minimally invasive method that addresses unmet clinical needs in rotator cuff repair. InSpace is CE Marked and commercialized in Europe and Israel and has been granted an Investigational Device Exemption (IDE) to initiate a pivotal human clinical study of the InSpace System in the United States.
Published at PRWeb
News: Conventus Orthopaedics announces milestone of 700+ Cage implantations
MINNEAPOLIS, Dec. 19, 2016 /PRNewswire/ -- Conventus Orthopaedics, Inc. announced that over 700 patients now have been treated with the industry's first expandable fracture cage, an innovative solution to fracture repairs in the upper extremity using a 3-dimensional approach. The Conventus Cage™, made of nitinol, a memory shape alloy, expands within the bone creating robust fixation and preventing further collapse of the fracture by providing a rigid internal scaffold upon completion of the procedure.
Conventus currently has five FDA-cleared indications in the upper extremity and the company is pursuing additional indications in the lower extremity and other areas of the skeletal anatomy. Clinical follow-up of the first cage implantations is over four years now, showing not only excellent fracture repair but also fewer complications and reduced pain with faster recoveries for the patients.
"For years, surgeons have expressed the need for more versatile and reliable surgical options to repair simple to complex fractures," said Paul Buckman, Conventus Orthopaedics CEO. "The Conventus Cages expand what is possible in patient care by enabling surgeons to repair a wider variety of fractures through less invasive means." Eric Fulkerson, M.D. of Muir Orthopaedics, Walnut Creek, CA said, "The Conventus Cage offers a solution that delivers reliably stable fracture repairs with consistently decreased recovery times and decreased pain for my patients. The innovative Cage design allows an expansion of fracture patterns treated with fixation as opposed to primary arthroplasty." Since the Cage is implanted into bone, instead of onto bone, the potential for interference of hardware, as well as the need for a future surgery to remove fixation, is significantly reduced. Andrew Schmidt, M.D., Chief of Orthopaedics, Hennepin County Medical Center, added, "For especially problematic fractures, such as those in the proximal humerus, the results after Cage fixation seem to be better, with more rapid return of motion and a dramatically lower incidence of surgical complications." Paul Paterson, M.D., orthopaedic surgeon in Buffalo, NY added, "The Conventus Cage offers tremendous stability of the fracture—better than plates and screws—through the use of 3-dimensional fixation. These fractures just do not move post repair."
Conventus' 3-dimensional Cage platform technology, emphasizes preservation of tissues and blood supply at the fracture site, creating a strong foundation by stabilizing bone fragments and facilitating early motion through less invasive procedures.
Conventus continues to expand their product portfolio and surgical applications in their quest to provide solutions throughout the entire musculoskeletal system.
For more information regarding use of the device please refer to www.conventusortho.com.
About Conventus Orthopaedics, Inc.
Conventus Orthopaedics, Inc. was founded by a team of medical device professionals and physicians with the sole purpose of improving patient care by creating a platform technology with less invasive solutions to a broad range of challenging periarticular fractures. Taking its name from the Latin word for coming together or union, Conventus Orthopaedics is focused on creating less invasive solutions for fractures in and around the joints. The company is dedicated to working with surgeons to improve healing and enable their patients' return to normal activities.
News: Carevature's Limited Market Launch in US Bri...
News: Intrinsic Therapeutics announces the Filing ...
News: CartiHeal Announces FDA IDE Approval of Its ...
News: ZipLine® Medical Receives China Food and Dru...
News: Anika Wins CE Mark Approval For ORTHOVISC®-T...
News: Stryker Orthopaedics to compensate additiona...
News: Amedica Announces Positive Scientific Data a...
News: Providence Medical Technology Announces New ...
News: Latest Australian Joint Registry Data Confir...
News: OrthoSpace Announces Publication of Positive...
News: Conventus Orthopaedics announces milestone o...
News: Vericel Corporation Announces Proposed Publi...
News: Safe Orthopaedics Receives CE Mark for a New...
News: aap concludes distribution contract with lea...
News: Significant Improvements in Knee Function af...
News: SpinalCyte, LLC Receives Institutional Revie...
News: National Joint Registry Analysis Finds Zimme...
News: Bioventus Enters Into New Agreement for DURO...
News: Zimmer Biomet Update on Product Supply Matte...
News: Zimmer Biomet Strengthens Spine Offering wit...
News: Arthrex Victorious in Patent Infringement La...
News: OMNIlife science™, Inc. Announces 10th Anniv...
News: Amplitude Surgical: Acquisition of a 50% Sta...
News: GE Makes Significant Progress with Investmen...
News: Abyrx® Announces Expansion of Exclusive, Wor...
News: Implanet Presents JAZZ Band Clinical Results...
News: JLL Partners and Water Street Announce New I...
News: International Cartilage Repair Society Launc...
News: Biomatlante invests in innovative solutions ...
A cohort study of 4,190 patients treated with low-...
News: Benvenue Medical Secures $60 Million Financi...
News: KYOCERA Medical Corporation Receives FDA 510...


It may be convenient to have another party hold property with the intent that the property revert back to the owner when the holder dies. One way to accomplish this is to sell property to the other party and contract with that party to name the owner as the beneficiary of the property in his or her will. The Estate of Gilbert No. 04–16–00641–CV (Tex. App.–San Antonio 2017) case provides an example of the hazards presented by these contracts if they do not follow Texas law.
The facts in this case are straightforward. In 2001, Gilbert's long term girlfriend sold her house to him in exchange for Gilbert naming her the sole beneficiary in his will. Gilbert did so in 2006 and updated the will in 2008 without changing the beneficiary. The couple split up in 2015 and Gilbert changed his will to name his son as his sole beneficiary. Gilbert died four months later. The girl friend sued Gilbert's estate for breach of contract and promissory estoppel.
the material provisions of the contract.
The key point is that the contract has to be in writing. Because the contract was not in writing in this case, the girlfriend dropped the contract claim. She still asserted that she was entitled to relief under promissory estoppel.
Texas law allows for promissory estoppel. This is a judicial doctrine that allows the court to put the aggrieved party back in the same condition as they were prior to the transaction giving rise to the claim.
The trial court concluded that promissory estoppel did not apply where the actual remedy was to pursue a breach of contract claim. On appeal, the appeals court agreed. The appeals court made it clear that breach of contract is the only remedy available where a decedent failed to live up to his agreement to name a party as the sole beneficiary of his estate. It does not apply in this type of probate litigation type of case.
This case stands as a warning to those who have or are considering contracting with another person for a will. The contract must be in writing to be enforceable in Texas.


text:
package e2e

import (
	"fmt"
	"time"

	"github.com/GoogleCloudPlatform/kubernetes/pkg/api"
	"github.com/GoogleCloudPlatform/kubernetes/pkg/client"
	"github.com/GoogleCloudPlatform/kubernetes/pkg/fields"
	"github.com/GoogleCloudPlatform/kubernetes/pkg/labels"

	. "github.com/onsi/ginkgo"
	. "github.com/onsi/gomega"
)

const (
	// How long to pause between polling node or pod status.
	poll = 5 * time.Second

	// How long nodes have to be "ready" before the reboot. They should already
	// be "ready" before the test starts, so this is small.
	nodeReadyInitialTimeout = 20 * time.Second

	// How long pods have to be "ready" before the reboot. They should already
	// be "ready" before the test starts, so this is small.
	podReadyBeforeTimeout = 20 * time.Second

	// How long a node is allowed to go from "Ready" to "NotReady" after a
	// reboot is issued before the test is considered failed.
	rebootNotReadyTimeout = 2 * time.Minute

	// How long a node is allowed to go from "NotReady" to "Ready" after a
	// reboot is issued and it is found to be "NotReady" before the test is
	// considered failed.
	rebootReadyAgainTimeout = 5 * time.Minute

	// How long pods have to be "ready" after the reboot.
	podReadyAgainTimeout = 5 * time.Minute
)

var _ = Describe("Reboot", func() {

	var c *client.Client = nil

	BeforeEach(func() {
		var err error
		c, err = loadClient()
		Expect(err).NotTo(HaveOccurred())
	})

	It("should reboot each node and ensure they function upon restart", func() {
		// This test requires SSH, so the provider check should be identical to
		// there (the limiting factor is the implementation of util.go's
		// getSigner(...)).
		provider := testContext.Provider
		if !providerIs("gce", "gke") {
			By(fmt.Sprintf("Skipping reboot test, which is not implemented for %s", provider))
			return
		}

		// Get all nodes, and kick off the test on each.
		nodelist, err := c.Nodes().List(labels.Everything(), fields.Everything())
		if err != nil {
			Failf("Error getting nodes: %v", err)
		}
		result := make(chan bool, len(nodelist.Items))
		for _, n := range nodelist.Items {
			go rebootNode(c, provider, n.ObjectMeta.Name, result)
		}

		// Wait for all to finish and check the final result.
		failed := false
		// TODO(mbforbes): Change to `for range` syntax and remove logging once
		// we support only Go >= 1.4.
		for _, n := range nodelist.Items {
			if !<-result {
				Failf("Node %s failed reboot test.", n.ObjectMeta.Name)
				failed = true
			}
		}
		if failed {
			Failf("Test failed; at least one node failed to reboot in the time given.")
		}
	})
})

// rebootNode takes node name on provider through the following steps using c:
//  - ensures the node is ready
//  - ensures all pods on the node are running and ready
//  - reboots the node
//  - ensures the node reaches some non-ready state
//  - ensures the node becomes ready again
//  - ensures all pods on the node become running and ready again
//
// It returns true through result only if all of the steps pass; at the first
// failed step, it will return false through result and not run the rest.
func rebootNode(c *client.Client, provider, name string, result chan bool) {
	// Get the node initially.
	Logf("Getting %s", name)
	node, err := c.Nodes().Get(name)
	if err != nil {
		Logf("Couldn't get node %s", name)
		result <- false
		return
	}

	// Node sanity check: ensure it is "ready".
	if !waitForNodeToBeReady(c, name, nodeReadyInitialTimeout) {
		result <- false
		return
	}

	// Get all the pods on the node.
	podList, err := c.Pods(api.NamespaceDefault).List(
		labels.Everything(), fields.OneTermEqualSelector(client.PodHost, name))
	if err != nil {
		Logf("Error getting pods for node %s: %v", name, err)
		result <- false
		return
	}
	podNames := make([]string, len(podList.Items))
	for i, p := range podList.Items {
		podNames[i] = p.ObjectMeta.Name
	}
	Logf("Node %s has %d pods: %v", name, len(podNames), podNames)

	// For each pod, we do a sanity check to ensure it's running / healthy
	// now, as that's what we'll be checking later.
	if !checkPodsRunning(c, podNames, podReadyBeforeTimeout) {
		result <- false
		return
	}

	// Reboot the node.
	Logf("Getting external IP address for %s", name)
	host := ""
	for _, a := range node.Status.Addresses {
		if a.Type == api.NodeExternalIP {
			host = a.Address + ":22"
			break
		}
	}
	if host == "" {
		Logf("Couldn't find external IP address for node %s", name)
		result <- false
		return
	}
	Logf("Calling reboot on %s", name)
	rebootCmd := "sudo reboot"
	if _, _, code, err := SSH(rebootCmd, host, provider); code != 0 || err != nil {
		Failf("Expected 0 exit code and nil error when running %s on %s, got %d and %v",
			rebootCmd, node, code, err)
		result <- false
		return
	}

	// Wait for some kind of "not ready" status.
	if !waitForNodeToBeNotReady(c, name, rebootNotReadyTimeout) {
		result <- false
		return
	}

	// Wait for some kind of "ready" status.
	if !waitForNodeToBeReady(c, name, rebootReadyAgainTimeout) {
		result <- false
		return
	}

	// Ensure all of the pods that we found on this node before the reboot are
	// running / healthy.
	if !checkPodsRunning(c, podNames, podReadyAgainTimeout) {
		result <- false
		return
	}

	Logf("Reboot successful on node %s", name)
	result <- true
}

// checkPodsRunning returns whether all pods whose names are listed in podNames
// are running.
func checkPodsRunning(c *client.Client, podNames []string, timeout time.Duration) bool {
	desc := "running and ready"
	Logf("Waiting up to %v for the following pods to be %s: %s", timeout, desc, podNames)
	result := make(chan bool, len(podNames))
	for ix := range podNames {
		// Launch off pod readiness checkers.
		go func(name string) {
			err := waitForPodCondition(c, api.NamespaceDefault, name, desc,
				poll, timeout, podRunningReady)
			result <- err == nil
		}(podNames[ix])
	}
	// Wait for them all to finish.
	success := true
	// TODO(mbforbes): Change to `for range` syntax and remove logging once we
	// support only Go >= 1.4.
	for _, podName := range podNames {
		if !<-result {
			Logf("Pod %s failed to be %s.", podName, desc)
			success = false
		}
	}
	Logf("Wanted all pods to be %s. Result: %t. Pods: %v", desc, success, podNames)
	return success
}

// waitForNodeToBeReady returns whether node name is ready within timeout.
func waitForNodeToBeReady(c *client.Client, name string, timeout time.Duration) bool {
	return waitForNodeToBe(c, name, true, timeout)
}

// waitForNodeToBeNotReady returns whether node name is not ready (i.e. the
// readiness condition is anything but ready, e.g false or unknown) within
// timeout.
func waitForNodeToBeNotReady(c *client.Client, name string, timeout time.Duration) bool {
	return waitForNodeToBe(c, name, false, timeout)
}

// waitForNodeToBe returns whether node name's readiness state matches wantReady
// within timeout. If wantReady is true, it will ensure the node is ready; if
// it's false, it ensures the node is in any state other than ready (e.g. not
// ready or unknown).
func waitForNodeToBe(c *client.Client, name string, wantReady bool, timeout time.Duration) bool {
	Logf("Waiting up to %v for node %s readiness to be %t", timeout, name, wantReady)
	for start := time.Now(); time.Since(start) < timeout; time.Sleep(poll) {
		node, err := c.Nodes().Get(name)
		if err != nil {
			Logf("Couldn't get node %s", name)
			continue
		}

		// Check the node readiness condition (logging all).
		for i, cond := range node.Status.Conditions {
			Logf("Node %s condition %d/%d: type: %v, status: %v",
				name, i+1, len(node.Status.Conditions), cond.Type, cond.Status)
			// Ensure that the condition type is readiness and the status
			// matches as desired.
			if cond.Type == api.NodeReady && (cond.Status == api.ConditionTrue) == wantReady {
				Logf("Successfully found node %s readiness to be %t", name, wantReady)
				return true
			}
		}
	}
	Logf("Node %s didn't reach desired readiness (%t) within %v", name, wantReady, timeout)
	return false
}

redpajama_set_name: RedPajamaGithub


This post, Ham, Veggie, and Hashbrown Casserole, may contain affiliate links. This means if you make a purchase through one of these links, Penguins in Pink will receive a commission at no additional cost to you.
Ham, Veggie, and Hashbrown casserole is one of my go-to weeknight meals. It does not require a lot of ingredients and most of the ingredients are staples in the house anyway. While chopping up the broccoli and cauliflower in the food processor does make a bigger mess, it gets extra veggies into everyone.
James is not a big veggie or potato eater but he will occasionally eat ham, veggie, and hashbrown casserole. Probably because it is so cheesy! I tend to make it on nights when he will not be home for dinner. The girls, however, love it. The leftovers keep well in the fridge for a few days too. While I tend to serve this casserole for dinner it does go well with eggs for breakfast or brunch.
Thaw broccoli and cauliflower on counter for about 15 minutes.
Empty bag broccoli into a food processor and pulse until finely chopped.
Place broccoli in a large bowl.
Empty bag of cauliflower into a food processor and pulse until finely chopped.
Place cauliflower in bowl with broccoli.
Add frozen hashbrowns to the bowl of veggies.
Mix in chopped ham and half the shredded cheddar cheese.
In a microwave safe dish, melt butter, milk, and salt.
Pour potato mixture into a 9×13 casserole dish.
Pour milk mixture over potato mixture.
Bake at 350 degrees for 50-60 minutes or until cheese is browned.
Ham, Veggie, and Hashbrown casserole is a great way to use leftover ham.
Broccoli, cauliflower, hashbrowns, and ham all combine with cheddar cheese to make this easy and hearty Ham, Veggie, and Hashbrown Casserole.
Pour potato mixture into a 9x13 casserole dish.
Looking for more casserole recipes? Check out my Recipes: Main Dishes board on Pinterest.


It seems that a lot of candidates see the Board of Education as a stepping stone to the Board of Supervisors and beyond. Generally speaking, I don't have a problem with that. We need experienced representatives at the higher levels of government and serving on a lower board or committee is a great way to gain that experience. The Board of Education, however, is a little bit different. It's actually a lot more important than most people think it is.
The Board's role in overseeing the school district is a crucial one; one that carries a lot of responsibility. Educating our youth is one of the most important jobs we, as a society, undertake. That's why our teachers have to have not only a college degree but also a credential and experience in the classroom working with a master teacher before they can take on the responsibility of a class of their own.
Likewise, the Board of Education is not just another committee but instead represents a significant duty to both current and future citizens.
My personal interest in the Board of Education stems primarily from my interest in and sense of obligation towards public education. I have no grand aspirations towards the Board of Education or Mayor's office, let alone Sacramento or Washington. If someone came along and said "here are the keys to the White House, please fix the country," I might consider it — wouldn't we all? — but in the real world, I want to do my part to give the children of San Francisco the best education and greatest opportunity possible.
As a member of the Board of Education, the only future that will concern me will be that of our students, not my own political future.
Ensuring that our children receive the best possible education takes a lot of hard work and dedication. That part's easy.
Unfortunately, it also takes money.
Please join our campaign to elect Roger Sinasohn. Your contribution will make a big difference and is greatly appreciated.


or DESIGNER EPIC™ machine. They will always be synchronized and available whenever you need them via WiFi.
The free App - mySewMonitor- provides you with real time updates on the status of your embroidery even when you're away from your DESIGNER EPIC™. The mySewMonitor App available for both Android and iOS.
The Wifi also gives you automatic software updats via Wifi - convenient and always up-to-date.
All this and a lot more on the DESIGNER EPIC™ sewing and embroidery machine.


text:
Shanghai Airport Terminal 1
Shanghai Airport Terminal 1 is the one dedicated to both domestic (on the right side) and international flights (on the left side).
Pudong Airport Terminal 1 counts with 204 check-in counters, 13 baggage carousels and a total number of 29 boarding gates. Aside, Terminal 1 counts with a new baggage handling system and also transfer facilities to ease the passenger processing.
Shanghai Airport Terminal 1 consists of three different levels:
- Level 1: Arrivals and baggage claim area. The area is divided into three different parts: Domestic arrivals, international arrivals and Macao and Taiwan arrivals.
All the arriving flights get into the Arrivals Hall, where several services are offered: Currency exchange, food, drink and retail concessions, tourist information, ground transportation.
- Level 2: Departures and check-in level. Serves most of the domestic flights as well as the regional ones. There is a transit hall in the centre that links with gate 16 (Concourse) and check-in counters C, G, H and J.
The gates that serve international flights are from 16 to 29. The gates that serve domestic flights are from 1 to 15.
There is a VIP Lounge "Sakura", located between gates 18-19.
- Level 3: It has the Immigration and security check-in as well as the check-in counters from A to M. In level 3 there are managed International flights to/from Taiwan, Macao and Hong Kong.
It has various VIP Lounges.
See the flights status in Shanghai Airport Terminal 1
Find the following services at Shanghai Airport Terminal 1:
Food, drink and retail concessions
Luggage storage and lockers
Showers (only in lounges)
See more Services at Shanghai Airport Terminal 1
Shanghai Airport Terminal 1 has at their passengers' convenience the following lounges:
First Class Lounge no.37: Location: International Terminal 1, on the south, close to Gate 37.
Golden Century VIP Lounge: Location: Domestic Terminal 1, airside, close to Gates 12-14.
First Class Lounge no.75: Location: Domestic Terminal 1, airside, second level, between Gates 8 and 9.
Book your stay at Shanghai Airport lounges

redpajama_set_name: RedPajamaCommonCrawl


REGISTER FOR FREE | ASK A QUESTION?
We Build native Android and iOS mobile apps for your e-store in less an a hour, powered by central mobile apps platform. Unlimited product listings, unlimited push notifications, real-time sync with your Shopify store, and a stunning and intuitive interface ensured by the best-in-class UI/UX, means while your users love your mobile app, you'll never again have to worry about inventory management and get to witness your business grow.
Try us, get your mobile app today. Book a demo and try your app today.
Shopify is the leading e-commerce platform that provides an affordable solution for e-commerce startups to build a powerful webstore with an appealing interface and the best features.
It brings the best marketing technology within the reach of startups to spread the word about their ecommerce ventures.
Shopify is easy to use and helps small and emerging firms across the world to grow into highly successful ecommerce enterprises.
Shopify is a hosted platform that takes care of everything from the modes of payment used to the security of the webstores built on its world-class platform.


Pitok (John) is a visual artist based in Sydney's inner west. Having graduated from UNSW Art & Design (formerly COFA), he has worked as a visual designer and art director commercially for the last 15 years. More recently he has been creating personal painted works using the medium gouache.
Pitok's lurid still life scenes bring together disparate ideas of personal culture and identity. Drawing from the traditions of Australian modernist painters and Japanese wood block prints, his works explore the notions of ones personal connection to time and place and how this can be both constructed and lost.
Pitok utilises still life scenes, as a means of enshrining personal objects of devotion, focusing on items that reluctantly cannot be disposed of. These objects become totems that tie us to a time and place. A memory, a person, an experience, a gesture, often something we cannot return to that has passed. These still life scenes represent the spaces we construct around us to reinforce a sense of identity and belonging.
In the last few years, having packed up two set's of grandparents homes, pitok has been on a personal journey processing these individual's lifetime of collected totems. What wisdom can be passed down or observed from these curated spaces. While the world moves at a fast consumer pace, why do we still long to collect items that have connection beyond the quick lifecycle of production and disposal.
Pitok's also looks at the construct of personal identity. Having lived in Japan and then returning to Australia, his works explore the masculine identity. How is it defined and how can it be expressed. Looking at it this intersection of cultural definition provides both a sense of conflict and insight.
Book pitok's painting workshops online, with ClassBento's exclusive money-back satisfaction guarantee and 10%+ loyalty bonus.
If you need a customised class (e.g. for a larger group, a special event, or more advanced learning, just get in touch with the pitok or us, and we'll make it happen.


text:
Means of payment and collection methods
Insolvency trend
Public debt (% GDP) 106.9 106.2 105.8 106.5
Flexible labour market
Full employment is one of the Federal Reserve's objectives
US dollar's predominant role in the global economy
Almost 60% of public debt held by residents
Highly attractive: leader in research & innovation, huge market
Reduced corporate tax rates
Increasing energy self-sufficiency
Low labour market participation
Households not very geographically flexible
High household debt (131% of gross disposable income)
Polarised political landscape
Lower fertility rate
Outdated infrastructure
Increasing inequalities
Slowdown in activity after a peak
Growth is slowing, reflecting business investment, which is set to be considerably less vibrant after being driven in 2018 by President Donald Trump's tax reforms (corporate tax cut from 35% to 21%). In addition, business profit margins are affected by increased input costs in connection with the customs duties imposed on more than half of Chinese imports, as well as on a wide range of products, including steel and aluminium. In this adverse environment for businesses, the US Federal Reserve (Fed) decided to reverse its monetary policy to support activity and cut its key interest rate in 2019, after hiking it from 1.5% to 2.5% in 2018. Household consumption should show resilience, thanks to the ongoing decline in the unemployment rate (3.6% in May 2019, the lowest in five decades) and the significant acceleration in real wages. As military spending surges in 2019 (USD 80 billion increase, or 0.4% of GDP), public consumption will contribute more to growth. Conversely, the business environment is much less favourable (slowdown in the main partner economies, protectionist reprisals by those same partners).
In addition, exports will slow significantly despite the signing of the USMCA trade deal (renegotiated NAFTA),. With imports decelerating at a slower rate thanks to resilient household consumption (despite protectionist measures), foreign trade will continue to weigh on growth.
Manufacturing – particularly the automotive sector – and construction are particularly affected by rising input costs. The energy sector is also struggling, due to the decline in oil prices.
Deterioration in the public and external accounts
The substantial government deficit is expected to further widen in 2019. While it increased sharply in 2018 with President Trump's tax reforms (USD 1.4 trillion in tax cuts over ten years, or about 0.7% of GDP per year), the deficit will continue to deteriorate, despite the strong economy, As a result, US public debt, which is among the highest in the world, will remain on an upward trend.
Substantial imports of consumer and capital goods have led to a chronic deficit in the goods balance, which is only partially offset by the surpluses in services and income (dividends from US investments abroad exceed remittances from investors and foreign workers). Despite the implementation of protectionist measures and the continued trade war with China (customs duties of 25% on USD 250 billion of Chinese imports), the current account deficit is expected to widen in 2019. With the deficit being financed by FDI and portfolio investment, the US net external position is structurally in deficit (42% of GDP at the end of June 2018).
Democrats regain control of the House of Representatives
Following the mid-term elections in November 2018, the Democrats regained the House of Representatives, taking 235 seats out of 435. Accordingly, any major new reform (health insurance, Mexican border, immigration, taxation) – other than the infrastructure plan – will now be almost impossible, since President Trump depends on Democrat support. In addition, the Democrats will be able to launch House investigations, for instance into Russian influence on the 2016 elections or President Trump's tax returns. However, the Republicans held onto the Senate, with 53 seats out of 100, and hence the important power to approve appointments of senior officials and Supreme Court judges. While the Democrats now have the power to launch proceedings to impeach President Trump, an impeachment would have very little chance of succeeding, because it would need a two-thirds majority in the Senate. President Trump will still be able to amend existing law by executive order, particularly in trade and foreign policy. Therefore, while his domestic policy is likely to be deeply affected by the new configuration, President Trump stick to the same line in international policy. Therefore, trade tensions with, among others, China, the European Union or India are expected to last, as are geopolitical tensions with Iran.
Last update : February 2019
Exporters should pay close attention to sales contract clauses on the respective obligations of the parties and determine payment terms best suited to the context, particularly where credit payment obligations are involved. In this regard, cheques and bills of exchange are very basic payment devices that do not allow creditors to bring actions for recovery in respect of "exchange law" (droit cambiaire) as is possible in other signatory countries of the 1930 and 1931 Geneva Conventions on uniform legal treatment of bills of exchange and cheques.
Cheques are widely used but, as they are not required to be covered at their issue, offer relatively limited guarantees. Account holders may stop payment on a cheque by submitting a written request to the bank within 14 days of the cheque's issue. Moreover, in the event of default, payees must still provide proof of claim. Certified checks offer greater security to suppliers, as the bank certifying the cheque thereby confirms the presence of sufficient funds in the account and makes a commitment to pay it. Although more difficult to obtain and therefore less commonplace, cashier's checks – cheques drawn directly on a bank's own account – provide complete security as they constitute a direct undertaking to pay from the bank.
Bills of exchange and promissory notes are less commonly used and offer no specific proof of debt. The open account system is only justified after a continuing business relationship has been established.
Transfers are used frequently – especially via the SWIFT electronic network, to which most American banks are connected, and which provides speedy and low-cost processing of international payments. SWIFT transfers are particularly suitable where real trust exists between the contracting parties, since the seller is dependent on the buyer acting in good faith and effectively initiating the transfer order.
For large amounts, major American companies also use two other highly automated interbank transfer systems – the Clearing House Interbank Payments System (CHIPS), operated by private financial institutions, and the Fedwire Funds Service System, operated by the Federal Reserve.
Amicable phase
Since the American legal system is complex and costly (especially regarding lawyers' fees), it is advisable to negotiate and settle out of court with customers wherever possible, or otherwise hire a collection agency.
The judicial system comprises two basic types of court: the federal District Courts with at least one such court in each state and the Circuit or County Courts under the jurisdiction of each state.
Fast-track proceedings
If the debt is certain and undisputed, US law provides for a "summary judgment" procedure, where a motion for summary judgment is based upon a claim by one party that all necessary factual issues are settled or that no trial is necessary. This is appropriate when the court determines there are no factual issues remaining to be tried, and therefore a cause of action or all causes of action in the complaint can be decided without a trial. If the judge decides that there are facts in dispute, the court will deny the motion for summary judgment and order a trial.
Ordinary proceedings
The vast majority of proceedings are heard by state courts, which apply state and federal law to disputes falling within their jurisdictions (i.e. legal actions concerning persons domiciled or resident in the state).
Federal courts, on the other hand, rule on disputes involving state governments, cases involving interpretations of the constitution or federal treaties, and claims above USD 75,000 between citizens of different American states or between an American citizen and a foreign national or foreign state body or, in some cases, between plaintiffs and defendants from foreign countries.
A key feature of the American judicial system is the pre-trial "discovery" phase, whereby each party may demand evidence and testimonies relating to the dispute from the adversary before the court hears the case. During the trial itself, judges give plaintiffs and their lawyers a considerable leeway to produce pertinent documents at any time and conduct the trial in general. This is an adversarial procedure, where the judge has more the role of an arbitrator, ensuring compliance with the procedural rules, although more and more practices enhances the role of the judge in the running of the case. The discovery phase can last several months, even years. It can entail high costs due to each adversary's insistence on constantly providing pertinent evidence (argued by each party), and involve various means – such as investigations, requests for supporting documents, witness testimony, and detective reports – which are then submitted for court approval during the final phase of the proceedings.
In civil cases, the jury determines whether the demand is justified and also determines the penalty to impose on the offender. For especially complex, lengthy, or expensive litigations, such as insolvency cases, courts have been known to allow creditors to hold as liable the professionals (e.g. auditors) who have counselled the defaulting party, where such advisors have demonstrably acted improperly.
Enforcement of a Legal Decision
Domestic judgments in the United States give the creditors additional rights, such as the seizure and selling of the debtor's assets or the garnishment of their bank account. As a federal state, decisions rendered in one of the country's states may be executed in another state's court, provided that the enforcing court considers that it is competent to enforce any judgement.
For foreign awards, each state has its own legislation. Nevertheless, they must be first recognised as domestic judgments. If a reciprocal recognition treaty exists, the requirement is fulfilled. However, in the absence of one, exequatur proceedings aim at ensuring enforcement in domestic court, after verifying the judgment meets certain criteria provided by the state law.
Insolvency Proceedings
Out-of court proceedings
Different state laws can propose out-of court proceedings in order to avoid any formal judicial proceedings, such as the Assignment for the benefit of creditors in the state of California, where a company turns over all of its assets to an independent third party, who liquidates and distributes them to all creditors in an equitable fashion.
Restructuring proceedings
Chapter 11 of the American Bankruptcy Code provides a distressed entity with the opportunity to preserve its business as a going concern while implementing an operation of financial restructuring. The debtor can seek to adjust its debt by reduction the amount owed or extending repayment terms. The debtor entity and its management continue to operate the business as the debtor-in-possession. The Bankruptcy Court supervises the proceedings.
According to Chapter 7 of the American Bankruptcy Code, the purpose of these proceedings is to implement an orderly liquidation of the distressed entity. The court-supervised process involves a trustee selling assets and distributing the proceeds to creditors in accordance with the statutory priorities provided in the Bankruptcy Code as well as pursuing available causes of action. The US Trustee appoints an independent interim trustee to administer the case. The interim trustee holds a meeting of creditors after the petition is filed. He is responsible for liquidating the estate's assets and distributing the proceeds to the creditors. The court supervises the proceedings. State law can also provide different mechanism for liquidation of a debtor's assets such as receivership.


text:
Q: Powering ir led with a 9V battery I'm using this break beam https://www.adafruit.com/product/2168 with an arduino. Currently both sides are are powered by the 5V from the arduino. I want to move the led half of the break beam to the far side of a doorway so it can be used to count foot traffic. Is there a way to hook up the ir led to a 9V battery without using a breadboard? Can I use electrical tape to affix a resistor between the battery and the led? Here is my project page https://devpost.com/software/door-counter thank you in advance for any advice on how to power the led separately from the the receiver.

A: Yes, you can but you have a few problems. A 9 V battery will discharge quickly when continuously driving the infra-red LED. And making electrical connections to a 9 V battery requires a snap-on battery connector.

Soldering is the only reliable way to connect the LEDtransmitter + resistor to the battery snap-on connector. But if you insist on proceeding, here's the circuit:

simulate this circuit – Schematic created using CircuitLab
An alternative circuit is shown, using two batteries in series (1.5 V each) that will last somewhat longer, yet still provide similar light intensity. Note that the 180 ohm resistor is contained inside the transmitter module. I'm guessing the internal circuit, since ADAfruit don't provide details.
Since the light beam expands as it travels further, you may find that detecting the beam across a doorway may be difficult, and will require larger current from the battery (too much for the LED to dissipate).
"Electrical tape" is used because of its protective insulating properties, not because it promotes electrical contact. It should not be used to secure a wrapped connection - reliability is not assured. Soldering or crimping is more reliable.

A: IR LED starts from 1.2~1.6V depending if pulsed up to 100mA with an ESR near 5 ohms, so 9V is very inefficient.
That's why LiPo 3.6V is preferred or some other low ESR , low voltage source. 9V is higher V ,higher ESR source, thus lower mAh capacity in terms of density or size.  You can trickle charge with 3.7~3.9V without fancy charger, if you can use adequate super low dropout , 3.3V LDO on arduino.

A: I might use a battery for a short-term test, but for any permanent or long-term installation, I would want the whole system, including the LED, powered from AC.  Otherwise you will have to replace the battery frequently, and won't know the battery needs replacement until you realize the counter is not working.

redpajama_set_name: RedPajamaStackExchange


text:
Home » Aircraft Models » Cargo Aircraft Model » No. 99 Squadron RAF C-17 Model, 1/116th Scale, Mahogany, USAF, Cargo
No. 99 Squadron RAF C-17 Model, 1/116th Scale, Mahogany, USAF, Cargo
No. 99 Squadron RAF C-17 Model, 1/116th Scale, Mahogany, USAF, Cargo quantity
SKU: 840231507219 Categories: Aircraft Models, C-17 Globemaster Model, Cargo Aircraft Model Tags: Boeing Model, C-17 Model, Cargo Model, Dad Christmas gift, Globemaster, Military models, No. 99 Squadron, RAF, Scale Model, USAF Model, Veteran gifts, Veterans Day
No. 99 Squadron RAF C-17 Model
Fly with the No. 99 Squadron RAF in this handcrafted C-17 Globemaster Model. Each piece is carved from wood and hand painted to provide a piece you'll love.
Number 99 Squadron is a squadron of the Royal Air Force which operates the Boeing C-17 Globemaster III strategic/tactical transport aircraft from RAF Brize Norton.
The squadron conducts global deployments on behalf of the British Armed Forces and the UK Government, notably delivering emergency aid during natural disasters and supporting military operations overseas.
No. 99 was a bomber squadron in both World War I and World War II. The squadron was the first RAF unit to receive the Avro Aldershot, Handley Page Hyderabad, Handley Page Hinaidi, Vickers Wellington, Bristol Britannia and Boeing Globemaster. In case of the Avro Aldershot the squadron was its only operator, as it is now for the Globemasters.
What would later become No. 99 (Madras Presidency) Squadron was originally formed at Yatesbury, Wiltshire, England on 15 August 1917 from elements supplied by No. 13 Training Squadron, RFC. It was equipped with de Havilland DH.9 bombers in 1918, deploying to France to form part of the Independent Air Force, the RAF's strategic bombing force. It flew its first mission on 21 May and continued to take part in large scale daylight raids against targets in Germany, sustaining heavy losses due both to the unreliable nature of the DH.9 and heavy German opposition. As an example, during one raid against railway targets in Saarbrücken on 31 July 1918, seven out of nine aircraft from 99 Squadron were shot down, with a further three DH.9s turning back with engine trouble before the formation crossed the enemy lines[1][8][9] 99 Squadron was withdrawn from the front line on 25 September to be re-equipped with de Havilland DH.9A bombers, and it was still in the process of converting when the war ended. During the war it had taken part in 76 bombing raids, dropping 61 tons of bombs and claiming 12 German aircraft, of which eight were during the raid of 31 July.
In 1919 the squadron was sent to India, flying patrols over the North-West Frontier from Mianwali and Kohat during the Mahsud and Waziristan campaigns. It was disbanded by being renumbered to No. 27 Squadron on 1 April 1920.
Inter-war period
No. 99 Squadron reformed on 1 April 1924 at Netheravon, Wiltshire, flying Vickers Vimys. In May 1924, it moved to RAF Bircham Newton in Norfolk, uniquely receiving the Avro Aldershot single-engined heavy bomber. These were replaced at the end of 1925 by twin-engined Handley Page Hyderabads, the squadron moving to RAF Upper Heyford in December 1927. In 1929, it again switched to new aircraft when it began receiving Handley Page Hinaidis, a radial engined derivative of the Hyderabad. By 1933, the Hinaidi, which was little improvement over bombers in use during the First World War, was recognised as obsolete, and in November the unit received the first production Handley Page Heyford heavy bombers. While these carried twice the bombload of the earlier aircraft, and had significantly better performance, they soon became outclassed. However, 99 Squadron, which had moved to RAF Mildenhall in November 1934, was obliged to retain the Heyford until October 1938, when it converted to Vickers Wellington monoplanes. In September 1935, "B" flight of 99 Squadron was split off to form 38 Squadron, while on 12 April 1937 the squadron again detached "B" flight, this time to form 149 Squadron.
Be the first to review "No. 99 Squadron RAF C-17 Model, 1/116th Scale, Mahogany, USAF, Cargo"
Avro Lancaster Model, RAF, WWII, Heavy Bomber, 1/68 Mahogany Scale Model
Avro Lancaster Model Fly in the classic Avro Lancaster Model in this hand crafted recreation. Each model is carved from wood and hand crafted to provide a piece you'll love. Length – 12.5 inches Wingspan – 18 inches The Avro … Read More
Airco DH-4 (N5997) Model, Mahogany, WWI, RAF, Army Air Corps, 1/30th Scale
Airco DH-4 (N5997) Model Fly in the classic Airco DH-4 (N5997) Model in this hand crafted recreation. Each model is carved from wood and hand crafted to provide a piece you'll love. Length – 12 inches Wingspan – 17 inches … Read More
Avro Vulcan Model, RAF, Strategic Bomber, Hawker Siddeley, 1/69 Mahogany Scale Model
Avro Vulcan Model Fly in the classic Avro Vulcan Model in this hand crafted recreation. Each model is carved from wood and hand crafted to provide a piece you'll love. Length – 15.5 inches Wingspan – 17 inches The Avro … Read More
Coast Guard 1713 Barbers Point C-130H Model, Lockheed Martin, Mahogany 1/74 (21″) Scale
Coast Guard 1713 Barbers Point C-130H Model A perfect gift or keepsake for any Coast Guard Aviator! This C-130H model has an 18 inch wingspan and is carved from Mahogany and carefully painted to provide the perfect display piece. The C-130H … Read More
VF-103 Jolly Rogers F-14b Model, 1/42 (18″) Scale, Mahogany, Navy, Fighter
VF-103 Jolly Rogers F-14b Model "Fear the Bones" of this beautifully carved wooden F-14 model of the VF-103 Jolly Rogers. This 18 inch model includes movable swept wings and a detailed paint scheme that will impress. We use only paint … Read More
VA-113 Stingers A-7 Corsair Model, LTV, 1/31 Mahogany Scale Model, Navy
VA-113 Stingers A-7 Corsair Model Recapture your time with the VA-113 Stingers and the awesome A-7 Corsair with this 17 inch wooden model. You will have a fantastic piece that you will always treasure.
VT-35 Stingrays TC-12 Huron Model, Beechcraft, Mahogany, 1/36 scale
VT-35 Stingrays TC-12 Model Celebrate a winging with a replica model of the TC-12 flown by the VT-35 Stingrays. Each model is carefully crafted and may be customized (allow for 60-90 days for custom work). Makes a memorable winging gift … Read More
VT-6 Shooters T-34C (Navy) Model
VT-6 Shooters T-34C Model 12 inch wooden model of the T-34C – a first for many a Naval Aviator of the VT-6 Shooters!. Let the T-34 start your model collection off right! *Pictures shown may or may not be exact … Read More
NAS Fallon SAR SH-60F Model,Sikorsky,Mahogany Scale Model
NAS Fallon SAR SH-60F Model Fly with the NAS Fallon SAR in this hand crafted SH-60F. Each model is carefully carved from wood and hand painted to provide a piece you'll treasure. Length – 16 inches Since 1972 the base … Read More


This foams & lathers like a soap. Organic Sugar Exfoliated the rough dry skin away, while the Jojoba Oil moisturizes new, supple, soft skin. Then the scrub rinses clean.
This has a light floral & magnolia scent with notes of blackberry. It has a soft, crisp & clean smell, that is great for summer!


Landscaping Loans from Gloan can help finance your next landscaping project.
Planting trees and plants, installing a pond, or building a fence for your home or business property increases your home value and value of the business value creating an aesthetically pleasing landscape for your family or customer and employees. Gloan understands landscaping is an expensive but a practical fix when needing to upgrade your home and business. Simple plans like planting privacy trees inbetween close lots is an easy way to alleviate the claustrophobic feeling and create a stress free environment. Great rates and easy approval with Gloan Landscaping Loans. Apply today and save!


One couldn't escape the media coverage of Pope Francis and his visit to the U.S. in September. I was working out at the gym, and on the TV in front of me on Fox News was the papal mass in Philadelphia. Millions flocked to see the pope, and to listen to his messages.
We studied the book of Colossians (my favorite book) at the church I have been attending. In Colossians 1, Paul writes that Jesus Christ is preeminent in all things. He reconciled us to himself by the blood of His cross. He is the head of the body, the Church. Our faith is founded on submission to Jesus Christ. It is through faith alone in Him that we are reconciled to God and receive eternal life.
The second largest religion in the world is Roman Catholicism. A "Catholic" is one who submits to the Magisterium, the teaching authority of Romanism. The Catechism of the Catholic Church (CCC) states: "The Roman Pontiff, head of the college of bishops, enjoys this infallibility in virtue of his office…The infallibility promised to the Church is also present in the body of bishops when, together with Peter's successor, they exercise the 'supreme Magisterium,' above all in an Ecumenical Council. When the Church through its supreme Magisterium proposes a doctrine 'for belief as being divinely revealed,' and as the teaching of Christ, the definitions 'must be adhered to with the obedience of faith.'" (CCC 891).
Submission to the Pope and bishops even extends to non-infallible declarations: "[even] without pronouncing in a 'definitive manner' they propose in the exercise of the ordinary Magisterium a teaching that leads to a better understanding of Revelation in matters of faith and morals. To this ordinary teaching the faithful 'are to adhere to it with religious assent' which, though distinct from the assent of faith, is nonetheless an extension of it." (CCC 892). In the Papal Bull Unum Sanctum (link), submission to the pope is forever imposed as a condition for salvation.
Roman Catholicism: Attend Mass on Sundays and Holy Days of Obligation and rest from servile labor.
Islam: Mandatory worship 5 times per day (Salat).
Roman Catholicism: Mandatory confession of sins to a priest at least once per year.
Islam: Mandatory pilgrimmage to Mecca at least once per lifetime (Hajj).
Roman Catholicism: Receive the Eucharist at least during the Easter season.
Islam: Testimony of faith – "There is no god but Allah. Muhammad is the Messenger of God" (Shahadah).
Roman Catholicism: Observe the days of fasting and abstinence.
Islam: Fasting in the month of Ramadan (Sawm).
Roman Catholicism: Provide for the needs of the Church.
For the Roman Catholic, faith is placed in the sacramental system of their Church and the "infallible" teachings of the Pope. Through this system, they are empowered to merit salvation by their good works. Revelation is ongoing, and includes Holy Tradition as delivered through the "successors to the apostles" – the Pope and bishops. Heaven is merited through faith and good works.
For the Muslim, faith is placed in the teachings of Muhammad, God's final prophet. Those who submit to Allah, believe the prophet, and do good works will go to heaven.
For the Christian, we believe that God has "delivered us from the domain of darkness and transferred us to the kingdom of his beloved Son, in whom we have redemption, the forgiveness of sins" (Col. 1:14). We submit to Jesus, our living head. It is through faith alone in Christ alone that we are reconciled to God. We do not trust in earthly rulers in any way for our acceptance with God. We do not yield "Obsequium Religiousum" (religious assent -link). We are like Bereans, who search the scriptures to see if any teaching is true. Colossians chapter 2 led me to flee the Roman Catholic religion. "See to it that no one takes you captive by philosophy and empty deceit, according to the elemental spirits of the world, and not according to Christ" (Col. 2:8). "I say this that no one may delude you with plausible arguments" (Col. 2:4). "Therefore, let no one pass judgment on you in questions of food or drink, or with regard to a festival, or a new moon or a Sabbath" (Col. 2:16). Let no one disqualify you, insisting on ascetisism…and not holding fast to the Head" (Col. 2:18).
"If then you have been raised up with Christ, seek the things that are above where Christ is, seated at the right hand of God. Set your mind on things that are above, not on things that are on earth" (Col. 3:1-2). Jesus Christ is our ruler; we submit to King Jesus. "Let the peace of Christ rule in your hearts…let the word of Christ dwell in you richly…and whatever you do, in word or deed, do everything in the name of the Lord Jesus, giving thanks to God the Father through him" (Col. 3:15-17).
I will NOT Submit my Will and Intellect, to a Man Made Religious System a.k.a Spiritual Babylon! Revelation 17 describes Mother Church( Roman Catholic Church ) the Mother of Harlots and Abominations!
In a Blog, the RC Apologist like to dismiss the fact that, the Catholic Church is the Roman Catholic Church! Are they afraid of the Romanism link? Do they not know, that are Totally SUBJECTED to the Papal Power and the Majesterium?
They need to read their Canon Laws!


text:
by Sean Burton on March 22, 2013
GI Joe: Retaliation
Dreamworks Animation's latest offering, The Croods, is the story of a caveman-family and their quest to find safe ground after an inventive and curious young boy, Guy (Ryan Reynolds), warns them of an impending apocalypse.
Led by Nicholas Cage as Grug, the overprotective father, the voice work is rather forgettable. It's not entirely the casts fault though: Chris Sanders' and Kirk De Micco's script is as formulaic as they come, with each character having a familiar personality. Emma Stone as Eep, the adventurous daughter, deserves credit however, giving the only real memorable turn. There are moments of Cage madness, but these are too few and far between to really make an impact. Ryan Reynolds goes through the motions as the inventive Guy, but his actions are a clear opposite to those of Grugs, making the morals that the film attempts to put across easier to identify.
Visually, The Croods is simply gorgeous. From the dull rock faces to the fantastic world they eventually arrive in, there's no part that isn't a pleasure to look at. It's also part of the films downfall, as it seems directors Sanders and De Micco have focussed their time on creating unusual (and colourful) dangers for the family instead of creating a refreshing and engaging narrative with interesting characters. It's surprisingly lacking in humour too, with the majority of the jokes already been revealed in the trailers.
Ultimately, The Croods is a disappointment. From its initial impressive trailers, it had the potential to be a highlight of the genre for 2013. The final result is a throwaway by-the-books family movie that lacks any charm, humour and originality. That said, it's visually stunning and is an acceptable piece of entertainment for a younger audience – just don't expect any material that's newer than the time the film is set in.
2013AnimationDreamworksEmma StoneNicholas CageRyan Reynolds
2013, Animation, Dreamworks, Emma Stone, Nicholas Cage, Ryan Reynolds
2013AnimationEmma StoneNicholas Cage
Leatherface returns in a surprisingly not-terrible prequel/sequel/reboot of the Texas Chainsaw franchise.
by Sean Burton on September 27, 2013
Hemsworth and Bruhl collide in one of 2013's finest.
A waste of 2 hours, R.I.P.D. should stay dead and buried in the bargain bin.
With its cliched storyline and below par acting, it's hard not to think that The Call should have been a straight-to-DVD release.
Pain & Gain isn't quite World's Strongest Man, but remains without a doubt intimidatingly buff.
It may not be the sequel we were all hoping for, but it's entertaining, brutal and above all satisfying.


text:
КК Рогашка је словеначки кошаркашки клуб из Рогашке Слатине. У сезони 2019/20. такмичи се у Првој А лиги Словеније и у Другој Јадранској лиги.

Историја
Клуб је основан 1960. године и у периоду од 1991. до 1997. године био је словеначки прволигаш. Услед финансијских проблема клуб је 1997. године угашен, али је већ 20. фебруара 1998. године обновљен под називом Рогашка 98. Од сезоне 2011/12. поново се такмичи у Првој А лиги Словеније. У сезонама 2014/15. и 2016/17. био је вицепрвак државе.

У сезони 2016/17. стигао је до полуфинала Алпе Адрија купа.

Успеси

Национални
 Првенство Словеније:
 Вицепрвак (2): 2015, 2017.

Учинак у претходним сезонама

Спољашње везе

 Званичан сајт клуба

Р

redpajama_set_name: RedPajamaWikipedia